miR-128 was fully functional in NSCLC tumorigenesis, partly by modulating lymphangiogenesis and revascularization by targeting VEGF-C and could simultaneously inhibit ERK, AKT, and p38 signaling pathways. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.